The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).
Fairooz F. Kabbinavar
No relevant relationships to disclose
Nazy Zomorodian
No relevant relationships to disclose
Matthew Rettig
No relevant relationships to disclose
Faraz Khan
No relevant relationships to disclose
Daniel Reif Greenwald
No relevant relationships to disclose
Brian DiCarlo
No relevant relationships to disclose
Sheldon J. Davidson
No relevant relationships to disclose
Ravindranath Patel
No relevant relationships to disclose
Lalita Pandit
No relevant relationships to disclose
Rosh Chandraratna
Employment or Leadership Position - Io Therapeutics
Consultant or Advisory Role - Io Therapeutics
Stock Ownership - Io Therapeutics
Martin Sanders
Employment or Leadership Position - Io Therapeutics
Consultant or Advisory Role - Io Therapeutics
Stock Ownership - Io Therapeutics